Investors need to see the forecast for Heat Biologics (HTBX)
What’s up with Heat Biologics?
Heat Biologics (HTBX) opened at $0.54, which means the stock is down 0.37% from yesterday’s closing price of 0.55. Today, the company has a high of $0.57 and a low of $0.53. The company has a market cap of $43.10 million with a 52-week high of $1.25 and a 52-week low of $0.20.
What about the future for Heat Biologics?
The high forecast for Heat Biologics is 5.00 while the low is 2.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Heat Biologics has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future. Based on this information HTBX seems to be a safe buy.
About Heat Biologics
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient’s T-cell mediated immune system against cancer. The company’s T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company’s ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.